An interventional study of Transdiagnostic single-session treatment in Anxiety Disorders, Depression and Stress Disorder, sponsored by Luleå Tekniska Universitet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.
Sponsored by Luleå Tekniska Universitet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Anxiety Disorders with a site in Sweden — 25 open to participants now, 38 under way, none of them phase 3. Anxiety Disorders · Sweden.
Among the 151 studies in Anxiety Disorders with a site in Sweden, this one is the 22nd largest by planned enrollment of the 132 interventional ones that give a count, is one of 11 that started in 2023, is one of 113 with no phase, reaches primary completion later than 7 of the 37 other live ones, and was the 107th registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →25 of the 151 studies in Anxiety Disorders with a site in Sweden are open now. Recruiting first, the newest first:
Uppsala University · Sites in Sweden
Ages 18–55
Region Stockholm · Sites in Sweden
Linkoeping University · Sites in Sweden
Ages 18+
Sahlgrenska University Hospital · Sites in Sweden
Ages 12+
Lund University · Sites in Sweden
Ages 8–17
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 11
First in 2001; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 97 across the 132 interventional studies, 196 across the 19 observational. Of the 103 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 151 have an industry lead sponsor. The 10 most frequent:
Luleå Tekniska Universitet is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Luleå Tekniska Universitet has 1 study filed under Anxiety Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Anxiety Disorders with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06657807Karolinska InstitutetOnline Cognitive Behavior Therapy for Anxiety Related to Pediatric Asthma | 2026-12 |
| NCT07637799Sahlgrenska University HospitalFeasibility Study of UP-A-AST Parent Group for Adolescents With Autism and Co-occurring Anxiety/Depression | 2026-12-30 |
| NCT03250026Göteborg UniversityCooperation for Primary Care Patients on Sick Leave for CMD: Care Manager and Workplace Intervention - CO-WORK-CARE | 2026-12-31 |
| NCT07706816Uppsala UniversityEvaluation of a Remote Behavioural Stress Recovery Intervention for Myocardial Infarction Patients Younger Than Fifty-five (BRIM-55): A Feasibility Study | 2027-01-31 |
| NCT04152512Karolinska University HospitalQuality of Life, Unmet Needs and Satisfaction With Care After Vulvar Cancer | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 151 studies in Anxiety Disorders with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. The main questions it aims to answer is:
The study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress.
The treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions.
The study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transdiagnostic single-session treatment
Behavioral: Transdiagnostic single-session treatment
Administered over 4 hour in group of 10 patients. Interventions are: Psychoeducation of emotions, De-fusion exercise, Mindfulness exercise, Interoceptive exposure, Behavioral activation
Anxiety, Depression and Stress symptoms post-treatment
Measured using DASS-21
Time frame: 3 weeks post-treatment
Anxiety, Depression and Stress symptoms follow-up
Measured using DASS-21
Time frame: 6 months post-treatment
Anxiety sensitivity post-treatment
Measured using BSQ, fear of bodily sensations related to anxiety
Time frame: 3 weeks post-treatment
Anxiety sensitivity follow-up
Measured using BSQ, fear of bodily sensations related to anxiety
Time frame: 6 months post-treatment
Experiential avoidance post-treatment
Measured using AFQ-Y8, psychological flexibility
Time frame: 3 weeks post-treatment
Experiential avoidance follow-up
Measured using AFQ-Y8, psychological flexibility
Time frame: 6 months post-treatment
Mindfulness post-treatment
Measured using FFMQ, mindfulness
Time frame: 3 weeks post-treatment
Mindfulness follow-up
Measured using FFMQ, mindfulness
Time frame: 6 months post-treatment
Alexithymia post-treatment
Measured using TAS-20, mindfulness
Time frame: 3 weeks post-treatment
Alexithymia follow-up
Measured using TAS-20, mindfulness
Time frame: 6 months post-treatment
Generalization
Qualitative interview with a few selected patients to review their experience of the treatment, its effectiveness and their ability to use the techniques taught.
Time frame: 6 months post-treatment
Additional treatment
It will be recorded if patients sought additional care after single-session treatment as well as type of care.
Time frame: 6 months post-treatment
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 14 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luleå Tekniska Universitet